EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment

Willy B Theel iD, Vivian D de Jong, Manuel Castro Cabezas, Diederick E Grobbee, Johan W Jukema, Stella Trompet

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.14368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Willy B Theel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Pravastatin, Obesity, Liver Cirrhosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liver fibrosis progression is influenced by older age and cardiometabolic risk factors such as obesity and is associated with an increased risk of cardiovascular events. While statins may protect against cardiovascular complications, their effects in elderly individuals with obesity and liver fibrosis are unclear.

Method

The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) database was used to evaluate the effect of pravastatin on major adverse cardiovascular events in an elderly population (>70 years). Subjects were categorized by BMI: lean (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PravastatinObesityLiver CirrhosisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesHumansAgedMaleFemaleBody Mass IndexProspective StudiesProportional Hazards ModelsAged, 80 and overStrokeMyocardial InfarctionOverweightAtrial Fibrillation

Stichwörter der Autor:innen

FIB‐4 indexcardiovascular diseaseliver fibrosisobesitystatin

Substanzen

PravastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Internal medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Obesity Center CGG, Rotterdam, The Netherlands.
  • Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Julius Clinical, Zeist, The Netherlands.
  • Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Internal Medicine, Section of Gerontology & Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Willy B Theel

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Theel, W. B., de Jong, V. D., Castro Cabezas, M., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2025). Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14368

Vancouver

Theel WB, de Jong VD, Castro Cabezas M, Grobbee DE, Jukema JW, Trompet S. Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14368

BibTeX
@article{Theel2025,
  author = {Theel, Willy B and de Jong, Vivian D and Castro Cabezas, Manuel and Grobbee, Diederick E and Jukema, Johan W and Trompet, Stella},
  title = {Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.14368}
}
Kostenlos starten →